Table 1.
Baseline characteristics of all patients, n (%)
| Characteristics | FOLFIRINOX (n = 86) | Gem + Nab-paclitaxel (n = 81) | P value |
| Age (yr) | 54 (30-78) | 65 (42-79) | < 0.001 |
| Male sex | 49 (57.0) | 37 (45.7) | 0.144 |
| ECOG-PS | 0.040 | ||
| 0 | 72 (83.7) | 57 (70.4) | |
| 1 | 14 (16.3) | 24 (29.6) | |
| Body mass index | 22.13 (16.49-31.63) | 21.97 (16.11-29.59) | 0.432 |
| Tumor location1 | 0.398 | ||
| Head and neck | 40 (46.5) | 32 (39.5) | |
| Body and tail | 46 (53.5) | 48 (49.3) | |
| Metastasis site | |||
| Liver | 57 (66.3) | 40 (49.4) | 0.027 |
| Lung | 9 (10.5) | 12 (14.8) | 0.397 |
| Bone | 4 (4.7) | 6 (7.4) | 0.5262 |
| Peritoneum (carcinomatosis) | 35 (40.7) | 42 (51.9) | 0.148 |
| Distant LN | 33 (38.4) | 28 (34.6) | 0.610 |
| Othersite (e.g. adrenal gland) | 14 (16.3) | 20 (24.7) | 0.177 |
| No. of metastasis site | 0.726 | ||
| 1 site | 39 (45.3) | 38 (46.9) | |
| 2 sites | 30 (34.9) | 24 (29.6) | |
| 3 or more | 17 (19.8) | 19 (23.5) | |
| Laboratory data (at diagnosis) | |||
| WBC count (cells/μL) | 6765 (2830-21880) | 6240 (2580-12240) | 0.068 |
| Neutrophil count (cells/μL) | 4660 (1610-18930) | 4045 (1410-8540) | 0.035 |
| Prothrombin time (INR) | 1.01 (0.80-1.28) | 1.00 (0.83-1.16) | 0.176 |
| Total bilirubin (mg/dL) | 0.7 (0.2-13.5) | 0.6 (0.2-23.4) | 0.200 |
| AST (IU/L) | 24 (9-204) | 22 (9-765) | 0.286 |
| ALT (IU/L) | 27 (5-192) | 17 (5-717) | 0.117 |
| Alkaline phosphatase (IU/L) | 116 (43-957) | 92 (37-2080) | 0.798 |
| CA 19-9 at diagnosis (U/mL) | 585.3 (3.4-20000) | 305.2 (0.6-20000) | 0.678 |
1
Except for one case that originated from an ectopic pancreas;
2
Fisher's exact test. Gem + nabPTX: Gemcitabine plus nab-paclitaxel; ECOG-PS: Eastern Cooperative Oncology Group performance status; LN: Lymph node; WBC: White blood cell; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CA: Carbohydrate antigen.